JP2025510642A5 - - Google Patents

Info

Publication number
JP2025510642A5
JP2025510642A5 JP2024555049A JP2024555049A JP2025510642A5 JP 2025510642 A5 JP2025510642 A5 JP 2025510642A5 JP 2024555049 A JP2024555049 A JP 2024555049A JP 2024555049 A JP2024555049 A JP 2024555049A JP 2025510642 A5 JP2025510642 A5 JP 2025510642A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
sequence shown
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024555049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510642A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/056397 external-priority patent/WO2023174897A1/en
Publication of JP2025510642A publication Critical patent/JP2025510642A/ja
Publication of JP2025510642A5 publication Critical patent/JP2025510642A5/ja
Pending legal-status Critical Current

Links

JP2024555049A 2022-03-14 2023-03-14 標的細胞の細胞表面に存在するヒトｓｒｒｍ２に結合する抗体を含む組成物 Pending JP2025510642A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22161839.0 2022-03-14
EP22161839 2022-03-14
PCT/EP2023/056397 WO2023174897A1 (en) 2022-03-14 2023-03-14 Composition comprising an antibody which binds to human srrm2 present on the cell surface of a target cell

Publications (2)

Publication Number Publication Date
JP2025510642A JP2025510642A (ja) 2025-04-15
JP2025510642A5 true JP2025510642A5 (https=) 2026-03-25

Family

ID=80738871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024555049A Pending JP2025510642A (ja) 2022-03-14 2023-03-14 標的細胞の細胞表面に存在するヒトｓｒｒｍ２に結合する抗体を含む組成物

Country Status (6)

Country Link
EP (1) EP4493587A1 (https=)
JP (1) JP2025510642A (https=)
KR (1) KR20250099050A (https=)
CN (1) CN119156400A (https=)
CA (1) CA3245743A1 (https=)
WO (1) WO2023174897A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025255706A1 (en) * 2024-06-11 2025-12-18 Zeno Therapeutics Pte. Ltd. Diagnosis and treatment of aml
WO2025054760A1 (en) * 2023-09-11 2025-03-20 Zeno Therapeutics (Shenzhen) Co. Ltd. Composition comprising an antibody which binds to human srrm2 present on the cell surface of a target cell
WO2025056603A1 (en) * 2023-09-11 2025-03-20 Eximmium Biotechnologies Gmbh Srrm2 binders for treating and diagnosing blood cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2595638T3 (es) * 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR

Similar Documents

Publication Publication Date Title
JP7854016B2 (ja) 腫瘍治療薬及びその応用
KR102713267B1 (ko) 암 및 다른 질환을 치료하기 위한 클라우딘 18.2에 특이적인 결합 분자, 이의 조성물 및 방법
JP7844558B2 (ja) リンパ球における阻害経路の中和
JP6767362B2 (ja) リンパ球における阻害経路の中和
US12252538B2 (en) Monoclonal antibodies against IgV domain of B7-H3 and uses thereof
KR20210109520A (ko) 항체 및 이의 용도
JP2025510642A5 (https=)
CN116261590B (zh) 抗cd3抗体以及其用途
JP2021522347A5 (https=)
US10533046B2 (en) Anti-CK8 antibodies for use in the treatment of colorectal cancers
JP2024530368A (ja) 抗体薬物複合体およびその用途
US20250179187A1 (en) Anti pd-l2 antibody
RS64388B1 (sr) Pd-1 blokada nivolumabom kod refraktornog hočkinovog limfoma
KR20240038043A (ko) 약학적 조성물 및 용도
US20230365676A1 (en) Cd33 antibodies
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
CN112805297B (zh) 抗人类pd-l1抗体及其用途
JP2015525075A (ja) Ｃａ２１５に対するヒト化抗体
JP2020508694A5 (https=)
JP2023530997A5 (https=)
CN114761042A (zh) Il-38特异性抗体
WO2023227115A1 (en) A method of treating solid tumor
RU2821703C2 (ru) Антитела, специфичные к btn2, и их применение
HK40120258A (zh) 治疗实体瘤的方法
JP2026514050A (ja) 活性化可能な抗ｃｔｌａ４抗体をペンブロリズマブと組み合わせて使用いたがんの治療方法